Day: May 10, 2023

VANCOUVER, British Columbia, May 10, 2023 (GLOBE NEWSWIRE) — Swiss Water Decaffeinated Coffee Inc. (TSX: SWP) (“Swiss Water” or “the Company”), a leading specialty coffee company and premium green coffee decaffeinator, today reported strong financial results for the three months ended March 31, 2023. 2023 First Quarter Financial and Operational HighlightsFirst quarter revenue was $49.0 million, an increase of 28% or $10.6 million when compared to the same period in 2022. This was a quarterly record for Swiss Water. Quarterly volumes increased by 21% compared to the same period in 2022, driven by an increased concentration of volume produced in advance of the Burnaby facility shutdown and an upcoming short period of reduced available capacity. North American business continued its strong growth trajectory with volumes up by 35%...

Raising Full Fiscal Year 2023 Guidance on Record Quarterly Performance ARLINGTON, Va., May 10, 2023 (GLOBE NEWSWIRE) — Fluence Energy, Inc. (Nasdaq: FLNC) (“Fluence” or the “Company”), a leading global pure-play provider of energy storage products and services as well as digital applications for renewables and storage, today announced its results for the three months ended March 31, 2023. Financial Highlights for Second Fiscal Quarter of 2023Record quarterly revenue of approximately $698 million which represents an increase of 104% year-over-year. GAAP gross profit margin improved to approximately 4.4%, compared to approximately negative 4.3% for the same quarter last year. Adjusted gross profit margin1 improved to approximately 4.6%, compared to approximately negative 3.3% for the same quarter last year. Net loss of $37.4 million,...

CALGARY, Alberta, May 10, 2023 (GLOBE NEWSWIRE) — Parex Resources Inc. (“Parex” or the “Company”) (TSX: PXT) is pleased to announce its financial and operating results for the three-month period ended March 31, 2023, and the declaration of its Q2 2023 regular dividend of C$0.375 per share. Parex also announces the pending retirement of Ken Pinsky, Chief Financial Officer and Corporate Secretary, who is electing to retire effective November 30, 2023. All amounts herein are in United States Dollars (“USD”) unless otherwise stated. Key HighlightsGenerated Q1 2023 funds flow provided by operations (“FFO”)(1) of $162 million and FFO per share(2)(3) of $1.49. The first well of the 2023 big ‘E’ exploration program, Chirimoya at VIM-43 (100% W.I.), successfully reached its target depth of roughly 17,500 feet;...

Riot Reports $73.2 Million in Total Revenue, and New All-Time Records in 2,115 Bitcoin Produced and Hash Rate Capacity of 10.5 EH/s CASTLE ROCK, Colo., May 10, 2023 (GLOBE NEWSWIRE) — Riot Platforms, Inc. (NASDAQ: RIOT) (“Riot” or “the Company”), an industry leader in Bitcoin (“BTC”) mining and data center hosting, reported financial results for the three-month period ended March 31, 2023. The unaudited financial statements are available on Riot’s website and here. “Riot achieved a number of important milestones and records during the first quarter of 2023,” said Jason Les, CEO of Riot. “In spite of damage to our immersion Buildings F and G during severe winter storms in Texas in late 2022, we successfully reached new all-time highs for miner deployment, total hash rate capacity, and monthly Bitcoin production. Our teams are also...

LAVAL, Québec, May 10, 2023 (GLOBE NEWSWIRE) — Savaria Corporation (“Savaria”) (TSX: SIS), a global leader in the accessibility industry, is pleased to announce its results for the first quarter of 2023. Highlights – Q1 2023 compared to Q1 2022Revenue was $211.6M compared to $183.5M in 2022, an increase of 15.3%, due to organic growth of 13.5% originating from all segments and positive foreign exchange impact of 1.8%; Gross profit was $72.0M, up $13.5M or 23.1%, representing 34.0% of revenue compared to 31.9% in Q1 2022; Operating income was $15.5M, up $6.6M or 75.1%, representing 7.3% of revenue compared to 4.8% in Q1 2022; Adjusted EBITDA* was $31.2M, up $6.8M or 27.8%,; Adjusted EBITDA margin* stood at 14.7%, up 140 bps compared to 13.3% in Q1 2022; Net earnings for the quarter were $6.0M, or $0.09 per share on a diluted basis,...

GERMANTOWN, Md., May 10, 2023 (GLOBE NEWSWIRE) — Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT), today provided a business update for the first quarter ended March 31, 2023. Vered Caplan, CEO of Orgenesis, said, “We achieved revenue of approximately $7.0 million for the first quarter of 2023, which reflects the continued progress of our POCare strategy.  We are currently focused on the implementation of our quality systems, as well as our GMP processes at the various POCare sites. We are also expanding our international management team with the support of Metalmark, our long-term partner and investor in our Morgenesis subsidiary.  We are working closely with international suppliers to standardize production in our POCare...

Fourth quarter as reported revenue increased 14%; 16% constant currency organic revenue growth Fourth quarter as reported earnings per share of $1.88; adjusted EPS of $2.30 Fiscal 2024 Outlook ProvidedDUBLIN, IRELAND , May 10, 2023 (GLOBE NEWSWIRE) —  STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2023 fourth quarter and full year ended March 31, 2023. Revenue as reported for the quarter increased 14% to $1.38 billion compared with $1.21 billion in the fourth quarter of fiscal 2022. Constant currency organic revenue (see Non-GAAP Financial Measures) increased 16% for the fourth quarter of fiscal 2023 as compared to the fourth quarter of fiscal 2022.   “We are pleased to end the year with strong performance,” said Dan Carestio, President and Chief Executive Officer of STERIS....

Bank celebrates 60 years in business and receives top customer satisfaction ranking for the third year in a row LAKEWOOD, Colo., May 10, 2023 (GLOBE NEWSWIRE) — FirstBank, one of the nation’s largest privately held banks with a focus on “banking for good,” released its first-quarter results. The bank reported the following quarterly results, representing performance from Dec. 31, 2022 to March 31, 2023:Net loan balance increased 1.9 percent to $16.4 billion. Total deposits decreased 2 percent to $25 billion. Total assets increased 3.6 percent to $28.8 billion. Net income was $110.3 million.“As a privately held company that’s been around for over 60 years, we continue to make decisions that set us up for a sustainable future,” said Jim Reuter, CEO of FirstBank. “We have experienced many economic cycles...

TORONTO, May 10, 2023 (GLOBE NEWSWIRE) — Wesdome Gold Mines Ltd. (TSX: WDO) (“Wesdome” or the “Company”) today announces first quarter (“Q1 2023”) financial results. All figures are stated in Canadian dollars unless otherwise noted. Warwick Morley-Jepson, Board Chair and Interim CEO commented, “The year is off to a solid start with combined production results of 28,368 ounces coming in ahead of budget. We continued to make excellent progress on the Kiena production ramp, currently at the 123 level. Once the ramp reaches the 129 level late this year and we can develop 129L station, we will be able to take advantage of the significant ounces per vertical metre increase which is expected to result in materially better unit economics in 2024. At Eagle River, production exceeded our internal targets. Grade reconciliation in the Falcon...

CTIM-76 IND filing on track for Q1 2024 Preclinical data on CLDN6 bispecific antibody CTIM-76 presented at AACR Annual Meeting 2023 Cash and cash equivalents of $29.8 million as of March 31, 2023 PHILADELPHIA, May 10, 2023 (GLOBE NEWSWIRE) — Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company dedicated to improving the lives of patients living with cancer, today announced its financial results for the first quarter ended March 31, 2023, and reported on recent and upcoming business highlights. “During the first quarter of this year, Context announced a portfolio prioritization to focus solely on the development of our preclinical asset CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is an immunotherapy designed to activate and direct a patient’s own immune cells to CLDN6-positive...